PARIS, FRANCE, 14 JANUARY 2026 - Ipsen (Euronext: IPN; ADR: IPSEY) announced today the presentation of 14 across multiple neurological conditions at the TOXINS 2026 conference (14-17 January) in ...
Interim data from the ongoing EPITOME trial1 showed that 45.7% of stroke survivors with paresis developed post-stroke spasticity within 1 year<1% of stroke survivors receive BoNT-A treatment for ...
Complete list of Ipsen presentations at TOXINS 2026: ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results